{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:48:16Z","timestamp":1744289296193},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ejso.2016.07.146","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T07:18:09Z","timestamp":1481354289000},"page":"619-624","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)"],"prefix":"10.1016","volume":"43","author":[{"given":"D.B.Y.","family":"Fontein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Charehbili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.R.","family":"Nortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Putter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Meershoek-Klein","family":"Kranenbarg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.C.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.H.","family":"van de Velde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2016.07.146_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12282-010-0239-0","article-title":"Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?","volume":"18","author":"Takei","year":"2011","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejso.2016.07.146_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ctrv.2013.06.001","article-title":"Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review","volume":"40","author":"Charehbili","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejso.2016.07.146_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.breast.2007.01.011","article-title":"Aromatase inhibitor-associated arthralgia syndrome","volume":"16","author":"Burstein","year":"2007","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2016.07.146_bib4","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/art.21364","article-title":"Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation","volume":"52","author":"Felson","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ejso.2016.07.146_bib5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3109\/13697137.2011.647839","article-title":"Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy","volume":"15","author":"Hadji","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.ejso.2016.07.146_bib6","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(02)11774-0","article-title":"Hot flushes","volume":"360","author":"Stearns","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2016.07.146_bib7","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3109\/02656736.2010.507235","article-title":"Feeling too hot or cold after breast cancer: is it just a nuisance or a potentially important prognostic factor?","volume":"26","author":"Kokolus","year":"2010","journal-title":"Int J Hyperth"},{"key":"10.1016\/j.ejso.2016.07.146_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4065\/78.5.603","article-title":"Skin blood flow in adult human thermoregulation: how it works, when it does not, and why","volume":"78","author":"Charkoudian","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejso.2016.07.146_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2007.10.004","article-title":"Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.ejso.2016.07.146_bib10","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1093\/annonc\/mds204","article-title":"Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients","volume":"23","author":"Fontein","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2016.07.146_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","article-title":"Tamoxifen, hot flashes and recurrence in breast cancer","volume":"108","author":"Mortimer","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2016.07.146_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","article-title":"Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial","volume":"9","author":"Cuzick","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2016.07.146_bib13","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.2012.45.3068","article-title":"Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis","volume":"31","author":"Fontein","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2016.07.146_bib14","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ejca.2014.05.010","article-title":"Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients \u2013 A phase II trial","volume":"50","author":"Fontein","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2016.07.146_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2016.07.146_bib16","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2016.07.146_bib17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-014-2873-2","article-title":"Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial","volume":"144","author":"Fontein","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2016.07.146_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2007.10.004","article-title":"Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejso.2016.07.146_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10549-014-2986-7","article-title":"A\u00a0prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI","volume":"146","author":"Lintermans","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2016.07.146_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jnci\/djs528","article-title":"Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy","volume":"105","author":"Marinovich","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.ejso.2016.07.146_bib21","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.ejso.2014.07.036","article-title":"Accuracy of MRI for treatment response assesment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer","volume":"40","author":"Charehbili","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2016.07.146_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-006-9253-5","article-title":"New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK","volume":"100","author":"Hayes","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"384","key":"10.1016\/j.ejso.2016.07.146_bib23","first-page":"9938","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"12","author":"Cortazar","year":"2014","journal-title":"Lancet"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316310113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316310113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T07:41:52Z","timestamp":1568619712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798316310113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0748798316310113"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2016.07.146","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology (EJSO)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2016.07.146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}